LQ23 

LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC₅₀ of 1.4 nM. LQ23 exhibits anti-inflammatory activity^[1].

IC₅₀: 1.4 nM (CLK2), 2.1 nM (CLK1), 3.2 nM (CLK4), 21.7 nM (DYRK1A), >100 nM (CLK3)

LQ23 (10-100 nM) dose-dependently inhibits SR protein phosphorylation in chondrocytes, and thereby regulates the selective cleavage of genes^[1].
LQ23 (10-100 nM) dose-dependently inhibits CHIR99021-stimulated Wnt-signaling in HEK-293T cells with IC₅₀ of 2.9 μM^[1].
LQ23 (30 nM) ameliorates osteoarthritis through promotes the bone mesenchymal stem cells (BMSC) differentation into chondrocytes and suppresses the cartilage degradation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LQ23 (1.5 μg/ kg, single IA injection) inhibits inflammation, protects cartilage and improves function in the monosodium iodoacetate (MIA)-induced and ACLT-pMMx-induced osteoarthritis in Sprague-Dawley rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

416.54

C₂₄H₂₄N₄OS

2997615-62-8

N[C@H](COC1=CC(C2=CC=C(C3=C2)NN=C3C#CC4=CSC=C4)=CN=C1)CC(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sun Y, Hu T, Zhang M, Song J, Qin Z, Liu M, Ji J, Li Z, Qiu Z, Bian J. Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis. J Med Chem. 2024 Mar 28;67(6):4603-4623.  [Content Brief]